ArticleJournal of nanobiotechnology2026
Ergostane steroid, as one of the major contributor to cranberry derived extracellular vesicle nanoparticles, restores ovarian function of murine premature ovarian failure.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fruit- and Vegetable-Derived Exosome-like Nanovesicles: A Review.Foods (Basel, Switzerland) · 2026Review
- Fucosterol from marine algae: a multifunctional marine phytosterol with health benefits-from dietary component to functional ingredient.Food chemistry: X · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundA high-fat and high-sugar (HFHS) diet can induce ovarian insufficiency and premature ovarian failure (POF) by inducing the abnormal expression of multiple metabolic pathways that makes treatment difficult. We previously evaluated cranberry (Vaccinium, Va)-derived extracellular vesicle nanoparticles (Va-PENs) for their therapeutic potential in HFHS diet-induced POF in mice and herein examined, in greater detail, the molecular mechanism(s) underlying Va-PENs action in the treatment of the condition.
methodsVa-PENs were isolated, purified, and subsequently fed to our HFHS-POF model mice. Conventional H&E and immunohistochemical staining methods were used to observe the pathologic changes and protein expression in the murine ovarian tissues. Liquid chromatography/tandem mass spectrometry high-throughput metabolomic analysis was used to investigate the distribution and content of various metabolites in Va-PENs, cranberry, and murine serum. Quantitative polymerase chain reaction and western-blot analyses were used to determine the mRNA and protein expression levels in cell proliferation and aging and mitochondrial function in ovarian granulosa cells of the model mice.
resultsOral administration of Va-PENs significantly improved the pathologic aging status of ovarian granulosa cells in the HFHS-POF mice, reduced the proportion of atretic follicles, and corrected sex hormone (anti-Müllerian hormone, estradiol, and follicle-stimulating hormone) concentrations and blood lipid disorders. High-throughput metabolomic analysis revealed ergostane steroids (particularly campestanol) as key bioactive components shared between Va-PENs and cranberry. Oral delivery of campestanol replicated the therapeutic effects of Va-PENs, restoring granulosa cell morphology, inhibiting follicular atresia, normalizing sex hormone levels, and reducing cellular senescence markers by modulating the expression of the cell cycle/senescence pathway.
conclusionOur findings indicated that Va-PENs exerted potent therapeutic effects in mice with HFHS diet-induced POF. One of the potential mechanisms was ergostane steroid, as one of the major contributor to Va-PENs, significant reduction in HFHS-POF symptoms via modulating the expression of the cell cycle/senescence pathway. This study presents a safe, plant-derived, nanovesicle-based strategy for restoring ovarian function after the induction of POF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.